Gabather AB (publ) - Asset Resilience Ratio
Gabather AB (publ) (GABA) has an Asset Resilience Ratio of 82.06% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Gabather AB (publ)'s Asset Resilience Ratio has changed over time. See financial flexibility index of Gabather AB (publ) to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Gabather AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Gabather AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.14 Million | 82.06% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.14 Million | 82.06% |
Asset Resilience Insights
- Very High Liquidity: Gabather AB (publ) maintains exceptional liquid asset reserves at 82.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gabather AB (publ) Industry Peers by Asset Resilience Ratio
Compare Gabather AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Gabather AB (publ) (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Gabather AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.06% | Skr3.14 Million ≈ $338.24K |
Skr3.83 Million ≈ $412.17K |
+34.16pp |
| 2024-12-31 | 47.90% | Skr878.00K ≈ $94.49K |
Skr1.83 Million ≈ $197.26K |
+32.76pp |
| 2023-12-31 | 15.14% | Skr1.11 Million ≈ $119.99K |
Skr7.36 Million ≈ $792.48K |
-77.75pp |
| 2022-12-31 | 92.89% | Skr6.27 Million ≈ $674.97K |
Skr6.75 Million ≈ $726.62K |
-3.57pp |
| 2021-12-31 | 96.46% | Skr14.85 Million ≈ $1.60 Million |
Skr15.39 Million ≈ $1.66 Million |
+0.32pp |
| 2020-12-31 | 96.14% | Skr30.92 Million ≈ $3.33 Million |
Skr32.16 Million ≈ $3.46 Million |
-1.32pp |
| 2019-12-31 | 97.46% | Skr44.90 Million ≈ $4.83 Million |
Skr46.07 Million ≈ $4.96 Million |
+5.79pp |
| 2018-12-31 | 91.67% | Skr16.65 Million ≈ $1.79 Million |
Skr18.16 Million ≈ $1.95 Million |
+15.40pp |
| 2017-12-31 | 76.27% | Skr36.74 Million ≈ $3.95 Million |
Skr48.18 Million ≈ $5.18 Million |
-4.14pp |
| 2016-12-31 | 80.41% | Skr27.94 Million ≈ $3.01 Million |
Skr34.75 Million ≈ $3.74 Million |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more